CL2023003124A1 - Anticuerpos anti-tslp modificados - Google Patents
Anticuerpos anti-tslp modificadosInfo
- Publication number
- CL2023003124A1 CL2023003124A1 CL2023003124A CL2023003124A CL2023003124A1 CL 2023003124 A1 CL2023003124 A1 CL 2023003124A1 CL 2023003124 A CL2023003124 A CL 2023003124A CL 2023003124 A CL2023003124 A CL 2023003124A CL 2023003124 A1 CL2023003124 A1 CL 2023003124A1
- Authority
- CL
- Chile
- Prior art keywords
- modified anti
- tslp antibodies
- tezepelumab
- tslp
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178915P | 2021-04-23 | 2021-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003124A1 true CL2023003124A1 (es) | 2024-04-26 |
Family
ID=81597885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003124A CL2023003124A1 (es) | 2021-04-23 | 2023-10-19 | Anticuerpos anti-tslp modificados |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240182558A1 (enExample) |
| EP (1) | EP4326762A2 (enExample) |
| JP (1) | JP2024516595A (enExample) |
| KR (1) | KR20230175245A (enExample) |
| CN (1) | CN117177992A (enExample) |
| AR (1) | AR125404A1 (enExample) |
| AU (1) | AU2022262006A1 (enExample) |
| BR (1) | BR112023022041A2 (enExample) |
| CA (1) | CA3216700A1 (enExample) |
| CL (1) | CL2023003124A1 (enExample) |
| IL (1) | IL307439A (enExample) |
| MX (1) | MX2023012325A (enExample) |
| TW (1) | TW202304980A (enExample) |
| WO (1) | WO2022226342A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| WO2024118542A1 (en) * | 2022-11-28 | 2024-06-06 | Takeda Vaccines, Inc. | A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions |
| EP4647084A1 (en) * | 2023-01-06 | 2025-11-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Method for treating asthma by using tslp antibody |
| TW202448501A (zh) | 2023-02-02 | 2024-12-16 | 美商麥迪紐有限責任公司 | 用抗ｔｓｌｐ抗體治療慢性鼻竇炎 |
| IL324470A (en) | 2023-05-18 | 2026-01-01 | Medimmune Llc | Treatment of corticosteroid-dependent asthma using anti-TSLP antibody |
| WO2025147632A1 (en) | 2024-01-05 | 2025-07-10 | Medimmune, Llc | Treatment of chronic obstructive pulmonary disease with anti-tslp antibody |
| WO2025221247A1 (en) | 2024-04-17 | 2025-10-23 | Amgen Inc. | Treatment of eosinophilic esophagitis with anti-tslp antibody |
| WO2025265071A1 (en) * | 2024-06-21 | 2025-12-26 | Paragon Therapeutics, Inc. | Antibodies that bind tslp and methods of use |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US8716451B2 (en) * | 2005-01-12 | 2014-05-06 | Kyowa Hakko Kirin Co., Ltd | Stabilized human IgG2 and IgG3 antibodies |
| US7982016B2 (en) * | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| ES2595638T3 (es) * | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| WO2012007495A1 (en) | 2010-07-15 | 2012-01-19 | F. Hoffmann-La Roche Ag | Antibodies specifically binding to human tslpr and methods of use |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| KR20170123315A (ko) * | 2015-03-11 | 2017-11-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Tslp 결합 단백질 |
| KR102666879B1 (ko) | 2017-04-12 | 2024-05-23 | 암젠 인크 | 항-tslp 항체를 이용한 천식의 치료 |
| JP7200134B2 (ja) | 2017-06-08 | 2023-01-06 | アムジエン・インコーポレーテツド | トルク駆動式薬物送達デバイス |
| ES2978396T3 (es) * | 2017-08-01 | 2024-09-11 | Amgen Inc | Sistemas y métodos para la preparación en tiempo real de una muestra de polipéptidos para el análisis por espectrometría de masas |
| MA50557A (fr) | 2017-11-10 | 2020-09-16 | Amgen Inc | Pistons pour dispositifs d'administration de médicament |
| EP4321870B1 (en) | 2018-03-13 | 2025-07-30 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| TW202541859A (zh) | 2018-10-15 | 2025-11-01 | 美商安進公司 | 具有阻尼機構之藥物遞送裝置及自動注射器 |
| WO2020081480A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
| AU2020288652A1 (en) | 2019-06-05 | 2021-11-18 | Amgen Inc. | Methods of identifying attributes of therapeutic proteins |
| EP4025602A4 (en) * | 2019-09-04 | 2023-12-13 | Biosion, Inc. | TSLP BINDING ANTIBODIES AND USES THEREOF |
-
2022
- 2022-04-22 KR KR1020237039566A patent/KR20230175245A/ko active Pending
- 2022-04-22 CN CN202280030029.7A patent/CN117177992A/zh active Pending
- 2022-04-22 BR BR112023022041A patent/BR112023022041A2/pt unknown
- 2022-04-22 EP EP22722641.2A patent/EP4326762A2/en active Pending
- 2022-04-22 WO PCT/US2022/025999 patent/WO2022226342A2/en not_active Ceased
- 2022-04-22 US US18/287,597 patent/US20240182558A1/en active Pending
- 2022-04-22 MX MX2023012325A patent/MX2023012325A/es unknown
- 2022-04-22 JP JP2023563978A patent/JP2024516595A/ja active Pending
- 2022-04-22 TW TW111115432A patent/TW202304980A/zh unknown
- 2022-04-22 AU AU2022262006A patent/AU2022262006A1/en active Pending
- 2022-04-22 IL IL307439A patent/IL307439A/en unknown
- 2022-04-22 CA CA3216700A patent/CA3216700A1/en active Pending
- 2022-04-22 AR ARP220101043A patent/AR125404A1/es unknown
-
2023
- 2023-10-19 CL CL2023003124A patent/CL2023003124A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240182558A1 (en) | 2024-06-06 |
| TW202304980A (zh) | 2023-02-01 |
| WO2022226342A2 (en) | 2022-10-27 |
| IL307439A (en) | 2023-12-01 |
| AR125404A1 (es) | 2023-07-12 |
| CA3216700A1 (en) | 2022-10-27 |
| EP4326762A2 (en) | 2024-02-28 |
| JP2024516595A (ja) | 2024-04-16 |
| CN117177992A (zh) | 2023-12-05 |
| WO2022226342A3 (en) | 2022-12-01 |
| BR112023022041A2 (pt) | 2023-12-26 |
| AU2022262006A1 (en) | 2023-10-19 |
| KR20230175245A (ko) | 2023-12-29 |
| MX2023012325A (es) | 2023-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003124A1 (es) | Anticuerpos anti-tslp modificados | |
| BR112022011421A2 (pt) | Inibidores da proteína mutante kras | |
| AR108240A1 (es) | Formulaciones que contienen anticuerpos | |
| EA201891694A1 (ru) | Фармацевтическая композиция, содержащая конструкты биспецифических антител | |
| BR112021012037A2 (pt) | Molécula anti-pd-1/il-7 bifuncional | |
| MX2019011496A (es) | Composiciones de niraparib. | |
| BR112021012040A2 (pt) | Molécula anti-pd-1/sirpa bifuncional | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| BR112019001179A2 (pt) | anticorpo biespecífico que exibe atividade alternativa aumentada de função de cofator fviii | |
| CO2023014181A2 (es) | Composiciones de anticuerpos anti-tslp y usos de las mismas | |
| MX2023014154A (es) | Anticuerpos anti-ccr8. | |
| MX384080B (es) | Composición acuosa que contiene dantroleno. | |
| AR132013A2 (es) | Composición de propionato de calcio y agua | |
| BR112018000118A2 (pt) | método para aumentar a reatividade da lignina, uma composição de resina compreendendo a mesma e uso da referida composição de resina | |
| MX2023001160A (es) | Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo. | |
| MX2021003430A (es) | Nuevos oxadiazoles. | |
| CL2019001747A1 (es) | Composición basada en compuestos de tiosulfinato y/o tiosulfonato para su uso en la prevención de infecciones bacterianas en animales acuáticos. | |
| CL2020002459A1 (es) | Variantes de anticuerpo c-terminales | |
| EA201890075A1 (ru) | Инъецируемые фармацевтические композиции лефамулина | |
| MX2019002248A (es) | Proteina de union al factor h modificada. | |
| JOP20240127A1 (ar) | مركبات ثنائي آزا سبيرو بها استبدال بكربونيل واستخدامها | |
| AR095399A1 (es) | Formulaciones con oxidación reducida, método | |
| MX2021010596A (es) | Composicion farmaceutica que contiene oseltamivir. | |
| EA202191345A1 (ru) | Стабильный состав глюкокортикоидов |